Wiley最新文献

{"title":"Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial.","authors":"Aída García-González, Alejandro Matamoros-Domínguez, Juan Manuel Espinosa-Cabello, Gisela Pérez-Muñoz, Manuel Jesús León Aranda, María Del Carmen Roque-Cuellar, Silvia García-Rey, Andrés Jiménez-Sánchez, Antonio Jesús Martínez-Ortega, Miguel Ángel Mangas-Cruz, Isabel Cerrillo, Javier S Perona, Pedro Pablo García-Luna, Elena María Yubero-Serrano, José María Castellano","doi":"10.1111/dom.71206","DOIUrl":"10.1111/dom.71206","url":null,"abstract":"<p><strong>Aims: </strong>Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive-derived matrices, may modulate AGE metabolism. In this prespecified, exploratory secondary analysis of the OLTRAD trial, we evaluated whether long-term intake of OA-enriched olive oil attenuates kidney function decline in patients with T2DM.</p><p><strong>Methods: </strong>In the OLTRAD randomised controlled trial, 97 patients with T2DM were assigned to consume OA-enriched olive oil (600 mg OA/kg) or control olive oil for 12 months, alongside standard therapy. Kidney outcomes included estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (uACR). Circulating AGEs (methylglyoxal [MG], carboxymethyllysine [CML]), enzymes involved in AGE metabolism (aldose reductase [AR], glyoxalase-I [GloxI]), and oxidative stress markers (ROS and MDA) were assessed.</p><p><strong>Results: </strong>OA-enriched olive oil attenuated eGFR decline relative to control, an effect restricted to participants with mildly impaired eGFR at baseline (60-90 mL/min/1.73 m²; time × group interaction p = 0.010), with no significant interaction among participants with normal baseline eGFR. OA-enriched oil also prevented the rise in uACR observed with control oil. Mechanistically, OA reduced AR concentration and increased GloxI activity, resulting in lower circulating MG, whereas CML remained unchanged. OA-enriched oil further reduced ROS and MDA levels, while MDA increased with control oil.</p><p><strong>Conclusions: </strong>In this exploratory, hypothesis-generating secondary analysis, long-term consumption of OA-enriched olive oil was associated with attenuated kidney function decline in patients with T2DM, an effect limited to those with baseline mildly impaired eGFR. These changes were associated with modulation of AGE-related pathways and reduced oxidative stress. As the trial was powered for glycemic control rather than renal outcomes, larger, adequately powered studies are needed to confirm these findings before their clinical relevance can be established.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov identifier: NCT06030544; https://clinicaltrials.gov/study/NCT06030544.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10195-10209"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Diabetes Risk Models Applied to the Prediction of Incident Dysglycaemia in African and European Populations.","authors":"Melony Fortuin-de Smidt, Patrik Wennberg, Hannah Maike Albers, Charles Agyemang, Felix P Chilunga, Rikard Landberg, Lisa K Micklesfield, Samuel N Darko, Julia Otten, Ellis Owusu-Dabo, Clemens Wittenbecher, Tommy Olsson, Julia H Goedecke, Ina Danquah","doi":"10.1111/dom.71285","DOIUrl":"10.1111/dom.71285","url":null,"abstract":"<p><strong>Aims: </strong>We evaluated overall and sex-specific performance of established diabetes risk models for predicting incident dysglycaemia in African and European populations.</p><p><strong>Materials and methods: </strong>We externally evaluated the African Diabetes Risk model, Finnish Diabetes Risk model, Epidemiological Study on the Insulin Resistance Syndrome model and the personal and clinical Framingham models. Evaluation was performed in three prospective cohorts: the Research on Obesity and Diabetes among African Migrants (RODAM-Pros; migrant and non-migrant Ghanaians; n = 1607), the Middle-aged Soweto cohort (MASC; urban Black South Africans; n = 515) and the Västerbotten Intervention Programme (VIP; Sweden; n = 3044). Dysglycaemia was defined according to American Diabetes Association criteria. Discrimination (c-statistic) and calibration were assessed before and after recalibration.</p><p><strong>Results: </strong>Dysglycaemia developed in 17.7% of RODAM-Pros participants, 35.0% of MASC participants and 27.5% of VIP participants, with median follow-up of 6.7, 6.7 and 9.9 years, respectively. All models demonstrated poor-to-modest discrimination (c-statistic < 0.7). Most models substantially underestimated risk. Recalibration eliminated systematic miscalibration and reduced calibration error to ≤ 2.3% in RODAM-Pros and VIP and ≤ 3.4% in MASC. Performance varied by sex and cohort.</p><p><strong>Conclusions: </strong>Existing diabetes risk prediction models can be applied to predict incident dysglycaemia in both Sub-Saharan African and European populations, but only after recalibration to local risk levels.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10814-10826"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial.","authors":"José Caballero-Corbalán, Per Lundkvist, Daniel Espes, Per-Ola Carlsson","doi":"10.1111/dom.71204","DOIUrl":"10.1111/dom.71204","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the effect of liraglutide on residual beta-cell function in adults with long-standing type 1 diabetes (T1D) and detectable C-peptide.</p><p><strong>Materials and methods: </strong>In this randomized, blinded, placebo-controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C-peptide were assigned to liraglutide or placebo for 52 weeks. Mixed-meal tolerance tests were performed at baseline and weeks 6, 52, and 65. The primary endpoint was change in stimulated C-peptide area under the curve from baseline to week 52.</p><p><strong>Results: </strong>Liraglutide did not improve stimulated C-peptide compared with placebo at week 52. In exploratory post hoc longitudinal analyses including the post-treatment period (weeks 0-65), stimulated C-peptide declined more steeply in the liraglutide group than in the placebo group, accompanied by increasing insulin requirements over time.</p><p><strong>Conclusions: </strong>In adults with long-standing T1D, liraglutide did not preserve stimulated C-peptide after 52 weeks. Exploratory post hoc longitudinal analyses suggested a steeper decline in stimulated C-peptide with liraglutide than with placebo.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10093-10098"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.","authors":"Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa","doi":"10.1111/dom.71233","DOIUrl":"10.1111/dom.71233","url":null,"abstract":"<p><strong>Aims: </strong>Type 2 diabetes drives the progression of metabolic dysfunction-associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium-glucose cotransporter 2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves liver histology in adults with biopsy-proven MASH and type 2 diabetes.</p><p><strong>Materials and methods: </strong>In this 52-week, open-label, randomised, parallel-group trial in Japan, adults with biopsy-confirmed MASH and type 2 diabetes received semaglutide plus luseogliflozin or semaglutide alone at antidiabetic doses. Paired liver biopsies at baseline and Week 52 were evaluated by blinded pathologists. Primary histological endpoints included resolution of MASH without worsening fibrosis, ≥ 1-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score without worsening fibrosis and ≥ 1-stage improvement in fibrosis without worsening MASH.</p><p><strong>Results: </strong>Sixty participants were randomised (combination, n = 24; monotherapy, n = 36). At Week 52, all histological endpoints numerically favoured combination therapy. Resolution of MASH without worsening fibrosis occurred in 34.9% versus 19.4%, ≥ 1-point improvement in the NAFLD activity score (NAS) in 75.5% versus 55.6% and ≥ 1-stage fibrosis improvement in 26.9% versus 13.9%. In the pre-specified per-protocol analysis, ≥ 1-point improvement in the NAS was nominally significant. Combination therapy reduced body weight, glycated haemoglobin levels, aminotransferase levels and FibroScan-derived liver stiffness.</p><p><strong>Conclusions: </strong>In the pre-specified full analysis set, combination therapy at antidiabetic doses did not significantly improve pre-specified histological endpoints compared with monotherapy. In the pre-specified per-protocol analysis, a nominal improvement in the NAS was observed. Combination therapy improved body weight, glycemic control, aminotransferase levels and liver stiffness, with no new safety concerns identified.</p><p><strong>Trial registration: </strong>UMIN Clinical Trials Registry (UMIN-CTR): UMIN000045003; Japan Registry of Clinical Trials (jRCT): jRCTs061210009.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10163-10172"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Whole Fruit Feijoa Powder for Type 2 Diabetes Risk Prevention: A Randomised Controlled Trial.","authors":"I A Mohamed, I R Sequeira-Bisson, J J Lim, L D Plank, R Murphy, S D Poppitt, J L Miles-Chan","doi":"10.1111/dom.71270","DOIUrl":"10.1111/dom.71270","url":null,"abstract":"<p><strong>Background: </strong>Low energy diets (LEDs) are effective for body weight (BW) loss and improvement of type 2 diabetes (T2D) risk biomarkers. Emerging evidence suggests that whole fruit feijoa powder, rich in polyphenols and abscisic acid, may further support T2D prevention. The FERDINAND study investigated whether daily consumption of a whole fruit feijoa powder enhanced LED-driven improvements in fasting plasma glucose (FPG), BW, and other metabolic markers.</p><p><strong>Methods: </strong>At in-clinic screening, 97 participants were enrolled into the trial and randomised to receive 1150 mg/day of whole fruit feijoa powder (Fx, n = 48) or Placebo treatment (n = 49) for 6 months. All participants underwent 2 months of LED-induced weight loss, followed by 4 months of dietary advice for weight loss maintenance. BW, FPG, and secondary outcomes including blood pressure (BP) were assessed at baseline (M0) and the end of months 2 (M2), 4 (M4), and 6 (M6). Data were analysed using linear mixed-effects models as intention-to-treat (ITT) with imputation for missing not-at-random data points.</p><p><strong>Results: </strong>BW decreased in both treatment groups during the 2-month LED, with a gradual upward trajectory over the subsequent 4 months (time_0-6m: p < 0.001). There was no difference in BW between Fx and Placebo over the 6-month intervention (treatment×time_0-6m: p = 0.74). FPG followed the weight loss trajectory in both treatment groups (time_0-6m: p < 0.001), but with no between-group interaction over 6 months (treatment×time_0-6m: p = 0.09, n = 97). Systolic BP (SBP), but not diastolic BP, declined over the 6 months between treatments (treatment×time_0-6m: p = 0.01) in all participants, with SBP in Fx lower than Placebo at M4 and M6 (p < 0.05, both).</p><p><strong>Conclusions: </strong>In adults with overweight (predominantly obesity) and prediabetes, Fx supplementation may enhance blood pressure improvement achieved through BW loss. The polyphenolic matrix of whole fruit feijoa, which contains a high proportion of catechins, may have contributed to vascular benefits.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10709-10724"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A stable floor beneath the overdose decline?","authors":"Wayne Kepner","doi":"10.1111/add.70552","DOIUrl":"10.1111/add.70552","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"3140-3141"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients.","authors":"Die He, Xi Zeng, Lei Yin, Yang Liu, Weiping Zhou, Xing Liu, Linghao Zhao","doi":"10.1002/ijc.70633","DOIUrl":"10.1002/ijc.70633","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) related to hepatitis B virus (HBV) infection predominantly affects males, yet few studies have investigated the association between sex hormones and HBV integrations, and their involvement in HCC prognosis. We assessed estrogen receptor alpha (ERα) and androgen receptor (AR) expression via immunohistochemistry on tissue microarrays constructed from 426 HBV-related HCC samples. HBV integration features were determined using HBV-captured sequencing data. Logistic regression models were utilized to evaluate the association between sex hormone receptor expression level and HBV integration features. Cox regression models, combined with machine learning (ML) methods, were implemented to investigate the prognostic value of sex hormone receptors and HBV integrations concerning overall survival. We found high AR expression level was significantly associated with higher HBV integration levels (adjusted odds ratio [aOR] = 1.84, 95% confidence interval [CI]: 1.09-3.11, P for trend = 0.012), TERT integration (aOR = 2.34, 95% CI: 1.16-4.74, P for trend = 0.047), intergenic integration (aOR = 2.25, 95% CI: 1.20-4.24, P for trend = 0.021), and promoter integration (aOR = 1.81, 95% CI: 1.00-3.31, P for trend = 0.034). The inclusion of sex hormone receptors and HBV integrations in the predictive models led to improvements across all performance metrics in the Cox regression analyses (AUC improvement: 0.014 [Training], 0.026 [Validation]) and the ML (AUC improvement: 0.022 [Training]), although a slight deterioration in performance was noted in the ML validation set. The results suggested a relationship between AR expression level and HBV integration events, as well as the potential utility of HBV integration biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"2347-2360"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148381295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Comments on \"Meat Intake and Risk of Gastric and Esophageal Adenocarcinoma in the European Prospective Investigation Into Cancer and Nutrition (EPIC) Study\".","authors":"Catalina Bonet, Antonio Agudo, Paula Jakszyn","doi":"10.1002/ijc.70622","DOIUrl":"10.1002/ijc.70622","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"2365-2366"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing Trends in Hospitalisation With Diabetic Ketoacidosis at Type 1 Diabetes Diagnosis Among Children and Youth in the United States and England, 2002-2020.","authors":"Chintan V Dave, Kristen Lloyd, Abner Nyandege, Jason Roy, Raquel López-Díez, Sally Radovick, Brian L Strom","doi":"10.1111/dom.71279","DOIUrl":"10.1111/dom.71279","url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of population-level data evaluating trends in the proportion of children and youth hospitalised with diabetic ketoacidosis (DKA) at the time of Type 1 diabetes (T1D) diagnosis.</p><p><strong>Methods: </strong>National Medicaid (US publicly insured claims), MarketScan (US commercially insured claims) and Clinical Practice Research Datalink (CPRD) (English electronic health record) data were used to create cohorts of children with incident T1D. DKA at diagnosis was defined as a DKA hospitalisation occurring within 30 days prior to the diagnosis of T1D. The likelihood of presenting in DKA was modelled using age, sex, race and community-level social vulnerability. Population-level T1D incidence trends were also assessed.</p><p><strong>Results: </strong>Among 116 845 patients (mean [SD] age: 10.4 [4.9]; 46.8% female), 48 291 (41.3%) presented in DKA. These proportions increased between 2002 and 2019, rising by 11.1% (from 34.4% to 45.5%) in Medicaid, 2.8% (from 42.0% to 44.8%) in MarketScan and 18.6% (from 17.9% to 36.5%) in CPRD, and further increasing in 2020 (Medicaid, 52.4%; MarketScan, 52.9%; CPRD, 44.1%). T1D incidence increased from 2002 to 2019 from 10 to 17, 12 to 20 and 5 to 13 per 100 000 children, respectively, reaching 21, 22 and 15 per 100 000 in 2020, respectively. DKA was higher among children aged 6 months to 2 years (70.4%), and among Black (45.4%) and Hispanic (45.4%) backgrounds. An increased relative risk of DKA was evident among children under 2 years: 1.97 (95% CI: 1.92-2.02), Black children: 1.14 (1.06-1.23), Hispanic children: 1.12 (1.10-1.15), and those residing in higher areas of social vulnerability: 1.20 (1.02-1.40).</p><p><strong>Conclusion: </strong>This study found a relative increase in the proportion of children presenting with DKA at T1D diagnosis, occurring in parallel with rising T1D incidence. This uptrend, which preceded but was exacerbated by the COVID-19 pandemic, underscores worsening epidemiological trends, especially notable in England and among publicly insured US children.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10615-10624"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-Dependent Accrual of Cardiorenal Benefit With SGLT2 Inhibitors in Chronic Kidney Disease: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.","authors":"Shotaro Yoshida, Mashiro Iwatsubo, Takahiro Nakamura, Makiko Oda, Yusuke Sakamaki","doi":"10.1111/dom.71195","DOIUrl":"10.1111/dom.71195","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10857-10861"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}